CKD Bio Corp. (KRX:063160)

CKD Bio Statistics

Total Valuation

CKD Bio has a market cap or net worth of KRW 113.29 billion. The enterprise value is 260.07 billion.

Market Cap	113.29B
Enterprise Value	260.07B

Important Dates

The last earnings date was Thursday, August 14, 2025.

Earnings Date	Aug 14, 2025
Ex-Dividend Date	Dec 27, 2024

Share Statistics

CKD Bio has 5.49 million shares outstanding.

Current Share Class	5.49M
Shares Outstanding	5.49M
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.05%
Owned by Institutions (%)	0.03%
Float	3.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.71
PB Ratio	0.86
P/TBV Ratio	0.90
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-11.24
EV / Sales	1.63
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-11.39

Financial Position

The company has a current ratio of 1.56, with a Debt / Equity ratio of 1.21.

Current Ratio	1.56
Quick Ratio	0.65
Debt / Equity	1.21
Debt / EBITDA	n/a
Debt / FCF	-6.97
Interest Coverage	-5.49

Financial Efficiency

Return on equity (ROE) is -16.26% and return on invested capital (ROIC) is -5.54%.

Return on Equity (ROE)	-16.26%
Return on Assets (ROA)	-4.96%
Return on Invested Capital (ROIC)	-5.54%
Return on Capital Employed (ROCE)	-10.76%
Revenue Per Employee	308.16M
Profits Per Employee	-44.57M
Employee Count	519
Asset Turnover	0.51
Inventory Turnover	2.04

Taxes

Income Tax	-3.66B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.74% in the last 52 weeks. The beta is 0.83, so CKD Bio's price volatility has been lower than the market average.

Beta (5Y)	0.83
52-Week Price Change	-10.74%
50-Day Moving Average	22,794.00
200-Day Moving Average	22,443.60
Relative Strength Index (RSI)	34.05
Average Volume (20 Days)	20,243

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CKD Bio had revenue of KRW 159.93 billion and -23.13 billion in losses. Loss per share was -4,216.38.

Revenue	159.93B
Gross Profit	6.95B
Operating Income	-25.06B
Pretax Income	-26.79B
Net Income	-23.13B
EBITDA	-7.40B
EBIT	-25.06B
Loss Per Share	-4,216.38

Balance Sheet

The company has 12.35 billion in cash and 159.13 billion in debt, giving a net cash position of -146.78 billion or -26,755.58 per share.

Cash & Cash Equivalents	12.35B
Total Debt	159.13B
Net Cash	-146.78B
Net Cash Per Share	-26,755.58
Equity (Book Value)	131.58B
Book Value Per Share	23,985.21
Working Capital	48.83B

Cash Flow

In the last 12 months, operating cash flow was -16.59 billion and capital expenditures -6.24 billion, giving a free cash flow of -22.83 billion.

Operating Cash Flow	-16.59B
Capital Expenditures	-6.24B
Free Cash Flow	-22.83B
FCF Per Share	-4,161.57

Margins

Gross margin is 4.35%, with operating and profit margins of -15.67% and -14.46%.

Gross Margin	4.35%
Operating Margin	-15.67%
Pretax Margin	-16.75%
Profit Margin	-14.46%
EBITDA Margin	-4.63%
EBIT Margin	-15.67%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 0.46%.

Dividend Per Share	100.00
Dividend Yield	0.46%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.02%
Shareholder Yield	0.48%
Earnings Yield	-20.42%
FCF Yield	-20.15%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on December 27, 2019. It was a forward split with a ratio of 1.05.

Last Split Date	Dec 27, 2019
Split Type	Forward
Split Ratio	1.05

Scores

CKD Bio has an Altman Z-Score of 1.23 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.23
Piotroski F-Score	1